Preventive treatment (episodic & chronic)
Health economics analysis (coming soon)
Acute treatment of episodic migraine
Adolescents with migraine
Comparison of Nerivio and medications
In-app behavioral intervention
Independent scientific support
Nerivio’s scientific reviews
Adolescents: Comparison to acute migraine medications
Migraine in adolescents is associated with poorer performance, and absence from school and social activities, during a particularly formative time in life. Providing teens with more effective and engaging treatments for migraine can have far-reaching positive effects over the course of their lives.
This study was a post hoc analysis of data from the open label multi-center clinical trial that demonstrated the efficacy and safety of Nerivio as an acute treatment for adolescents with migraine
The study compared the effectiveness of Nerivio to that of standard-care medications (i.e., over-the-counter medications and triptans), based on data from 35 chronic and episodic migraine patients in the age range of 12-17 who participated in the clinical trial. During the study, each participant treated their attacks with their preferred oral medication for the first four weeks, and then in the following four weeks treated their attacks with Nerivio (only). The participants rated their pain level prior to the treatment, and two hours after the beginning of the treatment, via the Nerivio app.
- Pain relief was achieved by 71% of the participants with Nerivio vs 57% with medications.
- Pain freedom was achieved by 37% of the participants with Nerivio vs. 9% of the participants with medications.
- Consistency of pain relief was achieved by 80% with Nerivio vs 57% with medications.
- Consistency of pain freedom was achieved by 40% of the participants with Nerivio, vs. 9% with medications.
Nerivio is an effective acute treatment for adolescent with migraine, with non-inferior efficacy compared to current acute migraine therapies.
Source: Hershey AD et al. Comparison of remote electrical neuromodulation (REN) and standard-care medications for acute treatment of migraine in adolescents: a post-hoc analysis. Pain Med. 2021:pnab197. doi: 10.1093/pm/pnab197. Epub ahead of print.